An interventional study of alcohol septal ablation in Hypertrophic Obstructive Cardiomyopathy, sponsored by Steen Hvitfeldt Poulsen. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by Steen Hvitfeldt Poulsen · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Cardiomyopathy, Hypertrophic with a site in Denmark — 2 open to participants now, 3 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · Denmark.
Among the 12 studies in Cardiomyopathy, Hypertrophic with a site in Denmark, this one is the 12th largest by enrollment, is the only one that started in 2019, is one of 2 with no phase, and was the 6th registered.
365 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 118 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →2 of the 12 studies in Cardiomyopathy, Hypertrophic with a site in Denmark are open now. Recruiting first, the newest first:
Morten Steen Kvistholm Jensen · Sites in Denmark
Ages 18+
Cytokinetics · Sites in Denmark, United States, Argentina and 16 more countries
Ages 18–85
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 82 Cardiomyopathy, Hypertrophic studies recruiting now, 56 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 7 · Phase 4 1
First in 2011; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 60 across 182 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 213 across the 12 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 12 have an industry lead sponsor. The 7 most frequent:
Steen Hvitfeldt Poulsen is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Steen Hvitfeldt Poulsen has 2 studies filed under Cardiomyopathy, Hypertrophic — fewer than ten, so there is no comparison to draw.
1 of the studies in Cardiomyopathy, Hypertrophic with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05569382Morten Steen Kvistholm JensenTreatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy | 2027-04-01 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Cardiomyopathy, Hypertrophic with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To examine patients with hypertrophic obstructive cardiomyopathy (HOCM) before and after septal alcohol ablation, to investigate the effect of the treatment in regards to changes in myocardial function, perfusion, invasive hemodynamics and exercise tolerance.
Patients with HOCM who develop symptoms of heart failure are treated initially with non-vasodilating ß-blockers or verapamil to decrease myocardial contractility and heart rate. A substantial part of patients remain symptomatic despite medical treatment. In these patients interventional or surgical treatments (septal reduction therapies (SRT)) to reduce left ventricular outflow tract obstruction (LVOTO) is considered in the presence of moderate to-severe symptoms (New York Heart Association - functional class (NYHA) III-IV) and/or recurrent exertional syncope and an LVOTO gradient ≥50 mm Hg. In some centers, invasive therapy is also considered in patients with mild symptoms (NYHA Class II) who have a resting or maximum provoked gradient of ≥50 mm Hg (with exercise or Valsalva's maneuver) and moderate-to-severe mitral valve regurgitation. Advanced treatment options are alcohol septal ablation (ASA) or surgical myectomy often combined with mitral valve reconstructive surgery. These treatments have similar outcomes in terms of gradient reduction, symptom improvement and exercise capacity
No previous trials have examined the effect of ASA in HOCM with respect to changes in central hemodynamics and myocardial performance during exercise.
24 HOCM patients will be examined prior to ASA, and approximately six-nine months after ASA.
The examination set-up consists of simultaneous 1) transthoracic echocardiography (TTE), 2) right heart catheterization (RHC) and 3) cardiopulmonary exercise test (CPX).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
injection of 1-4 mL of 96% ethanol into a septal perforator of the left anterior coronary artery to produce a myocardial infarction
Procedure: alcohol septal ablation
injection of 1-4 mL of 96% ethanol into a septal perforator of the left anterior coronary artery to produce a myocardial infarction
Pulmonary capillary wedge pressure (PCWP) during exercise
Change in PCWP at 75 watt (or maximum exercise, if this is \< 75 W)
Time frame: Changes will be evaluated after an expected average of 6-9 months after treatment
Pulmonary capillary wedge pressure (PCWP) at rest
Changes in PCWP at rest
Time frame: Changes will be evaluated after an expected average of 6-9 months after treatment
Peak oxygen uptake (VO2-max)
Changes in maximal oxygen consumption (L/min) measured during cardiopulmonary exercise test
Time frame: Changes will be evaluated after an expected average of 6-9 months after treatment
Work capacity
work capacity measured in watt during a cardiopulmonary exercise test
Time frame: Changes will be evaluated after an expected average of 6-9 months after treatment
LVOT gradient during maximum exercise
Changes of the LVOT gradient during maximum exercise, measured in mmHg during 2D echocardiography
Time frame: Changes will be evaluated after an expected average of 6-9 months after treatment
Coronary flow reserve
Changes in the ratio of maximum coronary blood flow (induced by infusion of adenosin) to resting coronary blood flow, estimated by 2D doppler echocardiography
Time frame: Changes will be evaluated after an expected average of 6-9 months after treatment
Changes in biomarkers
Changes in N-terminal pro-brain natriuretic peptide (NT-proBNP) ng/l and troponin T ng/l
Time frame: Changes will be evaluated after an expected average of 6-9 months after treatment
Change in GLS (%) at peak exercise
Change in global longitudinal strain (GLS) in % at peak exercise
Time frame: Changes will be evaluated after an expected average of 6-9 months after treatment
Changes of symptoms and quality of life estimated by KCCQ
Changes of symptoms and quality of life with Kansas City Cardiomyopathy Questionnaire (KCCQ) assessed by clinical evaluation
Time frame: Changes will be evaluated after an expected average of 6-9 months after treatment
Ran from May 2019 to primary completion in Oct 2023, 52 months.
Of 47 non-industry interventional studies with no phase under Cardiomyopathy, Hypertrophic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 52 months is above that.
Counting every sponsor, half of 52 studies reached it within 52 months; a quarter within 26 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiomyopathy, Hypertrophic →
Steen Hvitfeldt Poulsen